BARDA Exercises $6 Million Option for Aeolus’ Acute Radiation Syndrome Drug

The Biomedical Advanced Research and Development Authority is making use of $6 million worth of contract options with Aeolus in order to take advantage of benefits, such as an IND filing for Aeolus’ AEOL-10150.
Genetic Engineering & Biotechnology News